Document

0001628280-20-013559.txt : 20200914 0001628280-20-013559.hdr.sgml : 20200914 20200914164535 ACCESSION NUMBER: 0001628280-20-013559 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200731 FILED AS OF DATE: 20200914 DATE AS OF CHANGE: 20200914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHAMPIONS ONCOLOGY, INC. CENTRAL INDEX KEY: 0000771856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521401755 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11504 FILM NUMBER: 201173648 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 410-369-0365 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS BIOTECHNOLOGY, INC. DATE OF NAME CHANGE: 20070220 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS SPORTS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: INTERNATIONAL GROUP INC DATE OF NAME CHANGE: 19860319 10-Q 1 csbr10-q7312020.htm 10-Q Document

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)



þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended July 31, 2020



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to

Commission file number 001-11504

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as defined in its charter)



Delaware	52-1401755
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

One University Plaza, Suite 307	07601
Hackensack, New Jersey	(Zip Code)
(Address of principal executive offices)

(201) 808-8400

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	CSBR	Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act:

None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer þ	Smaller reporting company þ
			Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

The number of Common Shares of the Registrant outstanding as of September 4, 2020 was 12,727,888.

DOCUMENTS INCORPORATED BY REFERENCE - None

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JULY 31, 2020



	PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements.
	Condensed Consolidated Balance Sheets as of July 31, 2020 (unaudited) and April 30, 2020	4
	Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended July 31, 2020 and 2019	5
	Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity for the Three Months Ended July 31, 2020 and 2019	6
	Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2020 and 2019	7
	Notes to Unaudited Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

CHAMPIONS ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)



	July 31, 2020			April 30, 2020
	(unaudited)
ASSETS
Current assets:
Cash	$	6,943		$	8,342
Accounts receivable, net	5,039			4,770
Prepaid expenses and other current assets	360			385

Total current assets	12,342			13,497

Operating lease right-of-use assets, net	5,673			2,798
Property and equipment, net	4,434			3,993
Other long-term assets	36			128
Goodwill	335			335

Total assets	$	22,820		$	20,751

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	2,675		$	3,140
Accrued liabilities	2,154			2,502
Current portion of finance lease	72			125
Current portion of operating lease liabilities	515			503
Deferred revenue	5,669			5,815

Total current liabilities	11,085			12,085

Non-current operating lease liabilities	6,044			3,170
Other non-current liabilities	178			178

Total liabilities	$	17,307		$	15,433

Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 12,727,888 and 12,726,728 shares issued and outstanding as of July 31, 2020 and April 30, 2020, respectively	13			13
Additional paid-in capital	78,098			77,978
Accumulated deficit	(72,598		)	(72,673		)

Total stockholders’ equity	5,513			5,318

Total liabilities and stockholders’ equity	$	22,820		$	20,751

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in Thousands, Except Per Share Amounts)



	Three Months Ended July 31,
	2020		2019

Oncology services revenue	$	9,547	$	6,737

Costs and operating expenses:
Cost of oncology services	5,336		3,752
Research and development	1,597		1,303
Sales and marketing	1,208		870
General and administrative	1,382		1,426

Total costs and operating expenses	9,523		7,351

Income (loss) from operations	24		(614		)

Other income (expense):
Other income (expense)	64		(12		)

Income (loss) before provision for income taxes	88		(626		)
Provision for income taxes	13		15

Net income (loss)	$	75	$	(641	)

Net income (loss) per common share outstanding
basic	$	0.01	$	(0.06	)
and diluted	$	0.01	$	(0.06	)

Weighted average common shares outstanding
basic	12,727,275		11,619,538
and diluted	14,231,641		11,619,538

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Dollars in Thousands)



	Common Stock		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
	Shares	Amount	Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
Balance April 30, 2020	12,726,728	13	$	77,978	$	(72,673	)	$	5,318
Stock-based compensation	—	—	120		$	—		$	120
Issuance of common stock on exercise of stock options	1,160	—	—		$	—		$	—
Net income	—	—	—		75			75
Balance July 31, 2020	12,727,888	13	$	78,098	$	(72,598	)	$	5,513

	Common Stock		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
	Shares	Amount	Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
Balance April 30, 2019	11,619,538	12	$	72,924	$	(70,698	)	$	2,238
Stock-based compensation	—	—	131		—			131
Net loss	—	—	—		(641		)	(641		)
Balance July 31, 2019	11,619,538	12	$	73,055	$	(71,339	)	$	1,728

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands)



	Three Months Ended July 31,
	2020			2019
Operating activities:
Net income (loss)	$	75		$	(641	)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	120			131
Depreciation and amortization expense	277			182
Gain on termination of operating lease	(75		)	—
Operating lease right-of use assets	(67		)	98
Provision for doubtful accounts	(6		)	6
Changes in operating assets and liabilities:
Accounts receivable	(263		)	480
Prepaid expenses and other current assets	25			52
Accounts payable	(465		)	(82		)
Accrued liabilities	(348		)	(410		)
Other non-current liabilities	1			—
Operating lease liabilities	157			(42		)
Deferred revenue	(146		)	(53		)

Net cash used in operating activities	(715		)	(279		)

Investing activities:
Purchase of property and equipment	(718		)	(749		)
Refund of security deposit	92			—

Net cash used in investing activities	(626		)	(749		)

Financing activities:
Finance lease payments	(58		)	(7		)

Net cash used in financing activities	(58		)	(7		)

Decrease in cash	(1,399		)	(1,035		)
Cash at beginning of period	8,342			3,237

Cash at end of period	$	6,943		$	2,202

Non-cash investing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	3,872			3,205

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization, Use of Estimates and Basis of Presentation

Champions Oncology, Inc. (the “Company”) is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. Utilizing the TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, the Company offers multiple services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.

The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the three months ended July 31, 2020 and 2019, there were no revenues earned by these subsidiaries.

The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, or GAAP, has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2020, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2020. The results of operations for the interim periods are not necessarily indicative of the results of operations for a full fiscal year.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note 2. Significant Accounting Policies

Cash and Cash Equivalents

The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents. As of July 31, 2020 and April 30, 2020 the Company had no cash equivalents.

Liquidity

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services. For the three months ended July 31, 2020, the Company had net income of approximately $75,000 and cash used in operations of $715,000. As of July 31, 2020, the Company had an accumulated deficit of approximately $72.6 million, working capital of $1.3 million and cash of $6.9 million. We believe that our cash on hand, together with expected net positive cash used in operations for fiscal year 2021, are adequate to fund operations through at least 12 months from the filing of this 10-Q. However, should our revenue expectations not materialize, we believe we have cost reduction strategies that could be implemented without disrupting the business or restructuring the Company. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.

Leases

Effective May 1, 2019, the Company accounts for its leases under Accounting Standards Codification ("ASC") Topic 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease, if applicable, or the Company’s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term.

Earnings Per Share

Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s common stock purchase warrants and stock options.



	Three Months Ended July 31,
	2020		2019
Basic and diluted net (loss) income per share computation (dollars in thousands):
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Weighted Average common shares – basic	12,727,275		11,619,538
Basic net income (loss) per share	$	0.01	$	(0.06	)

Diluted income (loss) per share computation:
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Income (loss) available to common stockholders	$	75	$	(641	)

Weighted Average common shares	12,727,275		11,619,538
Incremental shares from assumed exercise of stock options	1,504,366		—
Adjusted weighted average share – diluted	14,231,641		11,619,538

Diluted net income (loss) per share	$	0.01	$	(0.06	)

The following table reflects the total potential share-based instruments outstanding at July 31, 2020 and 2019 that could have an effect on the future computation of dilution per common share, had their effect not been anti-dilutive:



	July 31,
	2020	2019
Stock options	2,276,263	2,374,875
Warrants	—	1,669,773

Total common stock equivalents	2,276,263	4,044,648

Income Taxes

Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient earnings history, a valuation allowance is established. Our ability to utilize net operating losses (“NOL”) carryforwards to offset our future taxable income would be limited if we have undergone or were to undergo an “ownership change” within the meaning of Section 382 of the Internal Revenue Code (the “IRC”). The Company adjusts the valuation allowance in the period management determines it is more likely than not that deferred tax assets will or will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. As of July 31, 2020 and April 30, 2020, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.

Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements. Tax positions include, but are not limited to, the following:


•	An allocation or shift of income between taxing jurisdictions;


•	The characterization of income or a decision to exclude reportable taxable income in a tax return; or


•	A decision to classify a transaction, entity or other position in a tax return as tax exempt.

benefit that is cumulatively greater than 50% likely to be realized. The Company recorded $178,000 and $178,000 of liabilities related to uncertain tax positions relative to one of its foreign operations as of July 31, 2020 and April 30, 2020, respectively.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at July 31, 2020 and April 30, 2020, and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.

The provision for income taxes for the three months ended July 31, 2020 and 2019 was $13,000 and $15,000, respectively, mainly attributable to taxable income earned in Israel.

Revenue Recognition

All revenue is generated from contracts with customers. The Company's arrangements are service type contracts that mainly have a duration of less than a year. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions.

Pharmacology Study, POS Services and Other Services

The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.

The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.

Variable Consideration

In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.

Trade Receivables, Unbilled Services and Deferred Revenue

In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from the timing of payment terms and when an input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer.

revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.

Accounting Pronouncements Being Evaluated

In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Simplifying the Accounting for Income Taxes. The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC Topic 740 and removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years with early adoption permitted. We are currently assessing the impact of this update on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as small reporting companies. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, "Leases", (Topic 842), which required the Company to recognize lease assets and lease liabilities (related to leases previously classified as operating under previous U.S. GAAP) on its consolidated balance sheet for all leases in excess of one year in duration. The ASU was effective for the Company on May 1, 2019. The Company elected to adopt ASU 2016-02 using the modified retrospective method and, therefore, have not recast comparative periods presented in its unaudited consolidated financial statements. As permitted under ASU 2016-02, the Company elected to account for the non-lease components together with the lease components as a single lease component. The Company recorded an operating lease right-of-use ("ROU") asset of $3.2 million, net of deferred rent of $900,000 and an operating lease liability of $4.1 million as of May 1, 2019. See Note 8 of this Form 10-Q for additional information and required disclosures. Under Topic 842, the Company determined if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. This ASU was effective for and adopted by the Company on May 1, 2020. The adoption had no material impact on our consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee share based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance was effective for the Company on May 1, 2019. The Company adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements.

On November 11, 2019, the FASB issued ASU 2019-08 which clarifies the accounting for share-based payments issued as consideration payable to a customer in accordance with ASC 606. Under the ASU, entities apply the guidance in ASC 718 to measure and classify share-based payments issued to a customer that are not in exchange for a distinct good or service (i.e., share-based sales incentives). The ASU was effective for the Company on May 1, 2020 and the adoption had no material impact on our consolidated financial statements.

Note 3. Accounts Receivable, Unbilled Services and Deferred Revenue

Accounts receivable and unbilled services were as follows (in thousands):



	July 31, 2020			April 30, 2020
Accounts receivable	$	2,633		$	2,655
Unbilled services	2,689			2,404
Total accounts receivable and unbilled services	5,322			5,059
Less allowance for doubtful accounts	(283		)	(289		)
Total accounts receivable, net	$	5,039		$	4,770

Deferred revenue was as follows (in thousands):



	July 31, 2020		April 30, 2020
Deferred revenue	$	5,669	$	5,815

Deferred revenue is shown as a current liability on the Company's condensed consolidated balance sheet.

Note 4. Revenue from Contracts with Customers

Oncology Services Revenue

The Company recognizes revenue under ASC 606, Revenue Recognition - Revenue from Customers ("ASC 606"). In accordance with ASC 606, revenue is recognized when, or as, a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services.

A performance obligation is a promise (or a combination of promises) in a contract to transfer distinct goods or services to a customer and is the unit of accounting under ASC 606 for the purposes of revenue recognition. A contract's transaction price is allocated to each separate performance obligation based upon the standalone selling price and is recognized as revenue, when, or as, the performance obligation is satisfied. The majority of the Company's contracts have a single performance obligation because the promise to transfer individual services is not separately identifiable from other promises in the contracts, and therefore, is not distinct.

The majority of the Company's revenue arrangements are service contracts that are complete within a year or less. There are a few contracts that range in duration between 1 and 3 years. Substantially all of the Company's performance obligations, and associated revenue, are transferred to the customer over time. Most of the Company's contracts can be terminated by the customer without cause. In the event of termination, the Company's contracts provide that the customer pay the Company for services rendered through the termination date. The Company generally receives compensation based on a predetermined invoicing schedule relating to specific milestones for that contract. In addition, in certain instances a customer contract may include forms of variable consideration such as performance increases or other provisions that can increase or decrease the transaction price. This variable consideration is generally awarded upon achievement of certain performance metrics. For the purposes of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount to be recorded is estimated based on the assessment of the Company's anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future.

Amendments to contracts are common. The Company evaluates each amendment which meets the criteria of a contract modification under ASC 606. Each modification is further evaluated to determine whether the contract modification should be accounted for as a separate contract or as a continuation of the original agreement. The Company accounts for amendments as a separate contract if they meet the criteria under ASC 606-10-25-12.

Other revenue represents services provided to the pharmaceutical and biotechnology companies. The Company does not consider these services part of their core product offerings.

The following tables represents disaggregated revenue for the three months ended July 31, 2020 and 2019:



	Three Months Ended July 31,
	2020		2019
Pharmacology services	$	9,413	$	6,530
Personalized oncology services	113		180
Other	21		27
Total oncology services revenue	$	9,547	$	6,737

Contract Balances

Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period. There were no material contract assets or liabilities recorded on the condensed consolidated balance sheets as of July 31, 2020 and April 30, 2020.

Note 5. Property and Equipment

Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer equipment and software. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to nine years. Property and equipment consisted of the following (table in thousands):



	July 31, 2020			April 30, 2020
Furniture and fixtures	$	238		$	180
Computer equipment and software	1,689			1,209
Laboratory equipment	5,437			4,818
Assets in progress	114			554
Leasehold improvements	4			4

Total property and equipment	7,482			6,765
Less: Accumulated depreciation	(3,048		)	(2,772		)

Property and equipment, net	$	4,434		$	3,993

Depreciation and amortization expense, excluding expense recorded under the finance lease, was $224,000 and $145,000 for the three months ended July 31, 2020 and 2019, respectively.

As of July 31, 2020 and April 30, 2020, property, plant and equipment included gross assets held under finance leases of $343,000 and $366,000, respectively. Related depreciation expense was approximately $53,000 and $37,000 for the three months ended July 31, 2020 and 2019.

Finance Lease

In November 2014, the Company entered into a finance lease for laboratory equipment. The lease had costs of approximately $149,000, at inception, through November 2019. The final lease payment under this finance lease of $2,000 was paid during the three months ended January 31, 2020. As of July 31, 2020 the asset has been fully depreciated and book value is nil.

was originally due to mature in July 2020, the Company decided to pay the outstanding balance on February 1, 2019. As a result, the entire outstanding balance of the lease was nil as of July 31, 2019.

In December 2019, the Company entered into a finance lease for laboratory equipment. The lease has costs of approximately $231,000, at inception, through November 2020. This lease expires December 2020. The current monthly finance lease payment is approximately $19,000. The future minimum lease payments remaining under this finance lease are $77,000. The present value of minimum future obligations is calculated based on interest rate of 4.75%. Depreciation and amortization expense related to this finance lease was $53,100 for the three months ended July 31, 2020.

Note 6. Share-Based Payments

The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.

Stock-based compensation expense was recognized as follows (table in thousands):



	Three Months Ended July 31,
	2020		2019
General and administrative	$	47	$	132
Sales and marketing	48		22
Research and development	4		3
Cost of oncology services	21		(26		)
Total stock-based compensation expense	$	120	$	131

Stock Option Grants

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2020 and 2019 were as follows:



	Three Months Ended July 31,
	2020	2019
Expected term in years	6	—
Risk-free interest rates	0.39%	—%
Volatility	72.64%	—%
Dividend yield	—%	—%

The weighted average fair value of stock options granted during the three months ended July 31, 2020 was $9.85. There was no stock options granted during the three months ended July 31, 2019.

The Company’s stock options activity for the three months ended July 31, 2020 was as follows:



	Directors and Employees		Non- Employees		Total		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2020	2,228,326		43,332		2,271,658		$	3.23	5.0	$	10,663,000
Granted	7,500		—		7,500		8.94		9.85
Exercised			(1,160	)	(1,160	)	4.20
Forfeited	(500	)	—		(500	)	2.51
Canceled	(312	)	(923	)	(1,235	)	4.95
Expired	—		—		—

Outstanding, July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Vested and expected to vest as of July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Exercisable as of July 31, 2020	1,942,264		15,418		1,957,682		2.85		4.21	$	11,810,000

Note 7. Leases

The Company accounts for its leases under ASU 2016-02, "Leases", Topic 842.

Operating Leases

The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease commencement date through the scheduled expiration date. Rent expenses totaled $307,000 and $239,000 for the three months ended July 31, 2020 and 2019, respectively. The Company considers its facilities adequate for its current operational needs.

The Company leases the following facilities:


•	One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2021. The Company recognized $20,000 and $24,000 of rental costs relative to this lease for the three months ended July 31, 2020 and 2019, respectively.


•	1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on January 11, 2017. The operating commencement date was August 11, 2017. This lease originally expired in August 2028.


◦	On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by six months. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029.

◦

In accordance with ASC 842, "Leases", the Company evaluated the first amendment and also performed a reassessment of the existing lease for Suite 025 to determine the impact of the six-month term extension. As a result of this assessment, the Company recognized an additional operating ROU asset and related operating lease liability for Suite 025 of $118,000 and $125,000, respectively, as well as an incremental net rent expense of $8,000 during the three months ended July 31, 2020. The Company did not recognize the incremental rental expense under this amendment during fiscal 2020 as the Expansion Premises lease commencement date was during fiscal 2021.


◦	Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $3.8 million, each, respectively.


◦	For the leases related to Piccard Drive, the Company recognized $244,000 and $151,000 of rental expense for the three months ended July 31, 2020 and 2019.

•

1405 Research Boulevard, Suite 125, Rockville, Maryland 20850 (“New Location”), which consists of laboratory and office space where the Company conducted operations related to its primary service offerings. The Company executed this lease on November 1, 2018. The operating commencement date was January 17, 2019. This lease was set to expire in April 2024. The Company recognized $43,000 and $64,000 of rental expense for the three months ended July 31, 2020 and 2019, respectively. The Company terminated this lease on June 30, 2020 and transitioned its activities from this location to the Expansion Premises, as defined above, during the first quarter of fiscal 2021. Upon lease termination, the Company recognized a decrease in the related operating ROU asset and operating lease liability of approximately $850,000 and $926,000, respectively, as well as a gain on lease termination of $76,000.

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):



	July 31, 2020		July 31, 2019
Operating lease right-of-use assets, net	$	5,673	$	3,103
Current portion of operating lease liabilities	515		457
Non-current portion of operating lease liabilities	6,044		3,553

As of July 31, 2020, the weighted average remaining operating lease term and the weighted average discount rate were 8.42 years and 6.10%, respectively.

Future minimum lease payments due each fiscal year as follows (in thousands):



2021	$	1,117
2022	1,851
2023	1,818
2024	1,844
2025	1,867
Thereafter	7,268
Total	$	15,765

Refer to Note 5, Property and Equipment, for more information on financing leases.

Note 8. Related Party Transactions

Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties.

Consulting Services

During the three months ended July 31, 2020 and 2019, the Company paid an affiliate of a board member $18,000 for consulting services unrelated to his duty as a board member. During the three months ended July 31, 2020 and 2019, the Company paid an affiliate of another board member $5,600 and 15,200, respectively, for consulting services unrelated to their duties as a board member. As of July 31, 2020, $7,400 was due to these related parties.

Note 9. Commitments and Contingencies

Risks and uncertainties related to Covid-19

on travel and mass gatherings to slow the spread of the virus. Employers are also required to increase, as much as possible, the capacity and arrangement for employees to work remotely. In addition, on March 11, 2020, the President of the United States issued a proclamation to restrict travel to the United States from foreign nationals who have recently been in certain European and Latin American countries. Although, to date, these restrictions have not impacted our operations, the effect on our business, from the spread of COVID-19 and the actions implemented by the governments of the United States and elsewhere across the globe, may worsen over time.

Any outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations. These could include disruptions or restrictions on our ability to travel, pursue partnerships and other business transactions, receive shipments of biologic materials, as well as be impacted by the temporary closure of the facilities of suppliers. The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver supplies to us on a timely basis. In addition, health professionals may reduce staffing and reduce or postpone meetings with clients in response to the spread of an infectious disease. Though we have not yet experienced such events, if they would occur, they could result in a period of business disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. However, as of the date of this Form 10-Q, we have not experienced a material adverse effect on our business nor the need for reduction in our work force; and, currently, and we do not expect any material impact on our long-term activity. The extent to which COVID-19 impacts our business will depend on future developments which are highly uncertain and cannot be predicted, including, but not limited to, new information which may emerge concerning the increased severity of COVID-19, the actions to contain COVID-19, or treat its impact.

Legal Matters

The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2020, as filed on Form 10-K.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2020, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q, if any. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required

by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview and Recent Developments

We are engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. Utilizing our TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized PDX models, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.

Our Platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs. We believe it costs up to $100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $3 million in the pre-clinical setting to approximately $150 million in phase III clinical trials. Simulating trials before executing them provides benefits to both pharmaceutical companies and patients. Pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our TOS program. We have previously disclosed that our POS program would not be the focus of our growth moving forward and this plan remains unchanged.

In December 2019, a novel strain of coronavirus, COVID-19, was first identified in Wuhan, China. This virus continues to spread globally and, as of July 2020, has spread to over 200 countries, including the United States. The spread of COVID-19 from China to other countries has resulted in the World Health Organization declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Employers are also required to increase, as much as possible, the capacity and arrangement for employees to work remotely. In addition, on March 11, 2020, the President of the United States issued a proclamation to restrict travel to the United States from foreign nationals who have recently been in certain European and Latin American countries. Although, to date, these restrictions have not impacted our operations, the effect on our business, from the spread of COVID-19 and the actions implemented by the governments of the United States and elsewhere across the globe, may worsen over time.

Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through cash, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services. For the three months ended July 31, 2020, the Company had net income of approximately $75,000 and cash used in operations of $715,000. As of July 31, 2020, the Company had an accumulated deficit of approximately $72.6 million, working capital of $1.3 million, and cash of $6.9 million. We believe that our cash on hand, together with expected positive cash flows from operations for fiscal year 2021, are adequate to fund operations through at least 12 months from the filing of this 10-Q. However, should our revenue expectations not materialize, we believe we have cost reduction strategies that could be implemented without disrupting the business or restructuring the Company. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.

Operating Results

The following table summarizes our operating results for the periods presented below (dollars in thousands):



	For the Three Months Ended July 31,
	2020		% of Revenue		2019			% of Revenue		% Change

Oncology services revenue	$	9,547	100.0	%	$	6,737		100.0	%	41.7	%

Costs and operating expenses:
Cost of oncology services	5,336		55.9		3,752			55.7		42.2
Research and development	1,597		16.7		1,303			19.3		22.6
Sales and marketing	1,208		12.7		870			12.9		38.9
General and administrative	1,382		14.5		1,426			21.2		(3.1	)

Total costs and operating expenses	9,523		99.8		7,351			109.1		29.5
Income (loss) from operations	$	24	0.2	%	$	(614	)	(9.1	)%	103.9	%



	For the Three Months Ended July 31,

Oncology Services Revenue

Oncology services revenue was $9.5 million and $6.7 million for the three months ended July 31, 2020 and 2019, respectively, an increase of $2.8 million or 41.7%. The increase in revenue for the three month period is due to increased sales, both in number and size of studies, an increase in demand for our services, the growth of the platform, and expansion of our product line. Additionally, customers are seeking more complex study designs and end point analysis testing, leading to larger contracts, which contributed to revenue growth.

Cost of Oncology Services

Cost of oncology services for the three months ended July 31, 2020 and 2019 were $5.3 million and $3.8 million, respectively, an increase of $1.6 million or 42.2%. For the three months ended July 31, 2020 and 2019, gross margins were 44.1% and 44.3%, respectively. The increase in cost of oncology services for the three-month period was mainly due to an increase in compensation and outsourced lab service expenses. With the exception of outsourced lab services, the overall expense increase is generally in line with the expected contribution based on the growth in revenue, study volume, and expansion into new services. Gross margin varies based on timing differences between expense and revenue recognition and was impacted by the increase in costs on growing study volume in advance of revenue recognition. The cost of outsourced lab services contributed to this effect.

Research and Development

Research and development expenses for the three months ended July 31, 2020 and 2019 were $1.6 million and $1.3 million, respectively, an increase of approximately $300,000 or 22.6%. The increase for the three month period is mainly due to increased compensation and lab supply expense as we continued to develop new service capabilities and endpoint testing analysis, and sequencing costs as we continued to characterize our TumorBank.

Sales and Marketing

Sales and marketing expenses for the three months ended July 31, 2020 and 2019 were $1.2 million and $870,000, respectively, an increase of $338,000, or 38.9%. The increase for the three month period is mainly due to compensation expense driven by the continued expansion of our sales force and commissions earned on increased sales.

General and Administrative

General and administrative expenses for both the three months ended July 31, 2020 and 2019 were $1.4 million. General and administrative expenses are primarily comprised of compensation, insurance, accounting fees, and depreciation expenses.

Inflation

Inflation does not have a meaningful impact on the results of our operations.

Cash Flows

The following discussion relates to the major components of our cash flows:

Cash Flows from Operating Activities

Net cash used in operating activities was $715,000 for the three months ended July 31, 2020 compared to net cash used in operating activities of $279,000 for the three months ended July 31, 2019, respectively. The decrease in cash from operating activities during the current period was primarily due to changes in current balance sheet accounts in the ordinary course of business, including an increase in net accounts receivable of $263,000 and a reduction in accounts payable and accrued expenses of approximately $813,000.

Cash Flows from Investing Activities

Net cash used in investing activities was $626,000 and $749,000 for the three months ended July 31, 2020 and 2019, respectively. Cash used in investing activities was primarily related to the purchase of lab equipment and the development of software required for the Company's new products and services.

Cash Flows from Financing Activities

Net cash used in financing activities was $58,000 for the three months ended July 31, 2020 compared to the net cash used in financing activities of $7,000 for the three months ended July 31, 2019, respectively. Cash used in financing activities resulted from a reduction in option exercises during the current period.

Critical Accounting Estimates and Policies

The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 28, 2020.

Recent Accounting Pronouncements

For detailed information regarding recently issued accounting pronouncements and the expected impact on our condensed consolidated financial statements, see Note 2, "Significant Accounting Policies" in the accompanying Notes to Condensed Consolidated Financial Statements included in Item 1 of this Report on Form 10-Q.

Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable to smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Chief Financial Officer, have concluded that our disclosure controls and procedures were effective as of July 31, 2020 at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item; however, the discussion of our business and operations should be read together with the Risk Factors set forth in our Annual Report on Form 10K filed with the Securities and Exchange Commission on July 28, 2020. Such risks and uncertainties have the potential to affect our business, financial condition, results of operations, cash flow, strategies or prospects in a material and adverse manner.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits



No.		Exhibit
31.1*		Section 302 Certification of Principal Executive Officer
31.2*		Section 302 Certification of Principal Financial Officer
32.1**		Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



101.INS*		XBRL Instance Document.
101.SCH*		XBRL Taxonomy Extension Schema Document.
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document.

* filed herewith

** furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	CHAMPIONS ONCOLOGY, INC.
	(Registrant)

Date: September 14, 2020	By:	/s/ Ronnie Morris
		Ronnie Morris
		Chief Executive Officer
		(principal executive officer)

Date: September 14, 2020	By:	/s/ David Miller
		David Miller
		Chief Financial Officer
		(principal financial and accounting officer)

EX-31.1 2 csbrq1731202010-qex311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Ronnie Morris, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s first fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: September 14, 2020	/s/ Ronnie Morris
	Ronnie Morris
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 csbrq1731202010-qex312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, David Miller, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: September 14, 2020	/s/ David Miller
	David Miller
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 csbrq1731202010-qex321.htm EXHIBIT 32.1 Exhibit

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Champions Oncology, Inc. (the “Company”) on Form 10-Q for the period ended July 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the U.S. Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. the Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: September 14, 2020	/s/ Ronnie Morris
	Ronnie Morris
	Chief Executive Officer
	(Principal Executive Officer)

Date: September 14, 2020	/s/ David Miller
	David Miller
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 5 csbr-20200731.xml XBRL INSTANCE DOCUMENT 0000771856 2020-05-01 2020-07-31 0000771856 2020-09-04 0000771856 2020-04-30 0000771856 2020-07-31 0000771856 2019-05-01 2019-07-31 0000771856 us-gaap:CommonStockMember 2020-07-31 0000771856 us-gaap:CommonStockMember 2019-04-30 0000771856 us-gaap:RetainedEarningsMember 2020-07-31 0000771856 us-gaap:AdditionalPaidInCapitalMember 2020-05-01 2020-07-31 0000771856 2019-07-31 0000771856 us-gaap:CommonStockMember 2019-07-31 0000771856 us-gaap:RetainedEarningsMember 2019-05-01 2019-07-31 0000771856 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0000771856 us-gaap:RetainedEarningsMember 2019-07-31 0000771856 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0000771856 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0000771856 us-gaap:CommonStockMember 2020-04-30 0000771856 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0000771856 2019-04-30 0000771856 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-07-31 0000771856 us-gaap:RetainedEarningsMember 2020-04-30 0000771856 us-gaap:RetainedEarningsMember 2019-04-30 0000771856 us-gaap:RetainedEarningsMember 2020-05-01 2020-07-31 0000771856 us-gaap:AccountingStandardsUpdate201602Member 2019-05-01 0000771856 us-gaap:WarrantMember 2019-05-01 2019-07-31 0000771856 us-gaap:EmployeeStockOptionMember 2019-05-01 2019-07-31 0000771856 us-gaap:EmployeeStockOptionMember 2020-05-01 2020-07-31 0000771856 us-gaap:WarrantMember 2020-05-01 2020-07-31 0000771856 us-gaap:ProductAndServiceOtherMember 2020-05-01 2020-07-31 0000771856 csbr:PersonalizedOncologyServicesMember 2020-05-01 2020-07-31 0000771856 us-gaap:ProductAndServiceOtherMember 2019-05-01 2019-07-31 0000771856 csbr:PersonalizedOncologyServicesMember 2019-05-01 2019-07-31 0000771856 csbr:PharmacologyServicesMember 2019-05-01 2019-07-31 0000771856 csbr:PharmacologyServicesMember 2020-05-01 2020-07-31 0000771856 csbr:FinanceLeasedAssetsMember 2020-05-01 2020-07-31 0000771856 2018-07-01 2018-07-31 0000771856 srt:MinimumMember 2020-05-01 2020-07-31 0000771856 2019-12-01 2019-12-31 0000771856 2019-11-01 2020-01-31 0000771856 2014-11-01 2019-11-30 0000771856 srt:MaximumMember 2020-05-01 2020-07-31 0000771856 csbr:FinanceLeasedAssetsMember 2019-05-01 2019-07-31 0000771856 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-07-31 0000771856 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-05-01 2020-07-31 0000771856 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-04-30 0000771856 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-05-01 2020-07-31 0000771856 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-04-30 0000771856 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-07-31 0000771856 2018-05-01 2019-04-30 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2020-05-01 2020-07-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2020-05-01 2020-07-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2019-05-01 2019-07-31 0000771856 us-gaap:CostOfSalesMember 2019-05-01 2019-07-31 0000771856 us-gaap:CostOfSalesMember 2020-05-01 2020-07-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2019-05-01 2019-07-31 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2019-05-01 2019-07-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2020-05-01 2020-07-31 0000771856 csbr:RockvilleMDMember 2020-07-31 0000771856 csbr:RockvilleMDNewLocationMember 2020-06-30 2020-06-30 0000771856 2019-05-01 0000771856 csbr:RockvilleMDNewLocationMember 2020-06-30 0000771856 csbr:RockvilleMDMember 2020-05-01 2020-07-31 0000771856 csbr:RockvilleMDNewLocationMember 2020-05-01 2020-07-31 0000771856 csbr:RockvilleMDMember 2019-05-01 2019-07-31 0000771856 csbr:CorporateHeadquartersMember 2020-05-01 2020-07-31 0000771856 csbr:RockvilleMDNewLocationMember 2019-05-01 2019-07-31 0000771856 csbr:RockvilleMDMember 2020-06-01 0000771856 csbr:CorporateHeadquartersMember 2019-05-01 2019-07-31 0000771856 csbr:BoardMemberTwoMember srt:BoardOfDirectorsChairmanMember 2019-05-01 2019-07-31 0000771856 csbr:BoardMemberTwoMember srt:BoardOfDirectorsChairmanMember 2020-05-01 2020-07-31 0000771856 csbr:BoardMemberOneMember srt:BoardOfDirectorsChairmanMember 2020-05-01 2020-07-31 0000771856 csbr:BoardMemberOneMember srt:BoardOfDirectorsChairmanMember 2019-05-01 2019-07-31 iso4217:USD xbrli:shares iso4217:USD csbr:subsidiary xbrli:pure xbrli:shares 554000 114000 266000 231000 149000 11000 19000 42000 -157000 98000 -67000 7268000 2 8000 0.0475 0 92000 6000 -6000 1235 312 923 P9Y9M36D 4.95 -1300000 false --04-30 Q1 2021 2020-07-31 10-Q 0000771856 12727888 false Non-accelerated Filer Yes CHAMPIONS ONCOLOGY, INC. false true

3140000

2675000

2655000

2633000

5059000

5322000

4770000

5039000

2502000

2154000

2772000

3048000

77978000

78098000

131000

120000

900000

131000

-26000

132000

3000

22000

21000

47000

4000

48000

120000

289000

283000

4044648

2374875

1669773

2276263

20751000

22820000

13497000

12342000

1209000

1689000

8342000

6943000

3237000

2202000

8342000

6943000

-1035000

-1399000

0.001

200000000

12726728

12727888

12726728

12727888

13000

5815000

5669000

5815000

5669000

3752000

5336000

145000

37000

53000

224000

182000

277000

7400

-0.06

0.01

-0.06

0.01

125000

72000

77000

7000

2000

58000

366000

343000

53100

180000

238000

76000

75000

1426000

1382000

335000

-626000

88000

15000

13000

-82000

-465000

-480000

263000

-410000

-348000

-53000

-146000

1000

-52000

-25000

1504366

4000

0.061

15765000

1851000

1867000

1844000

1818000

1117000

15433000

17307000

20751000

22820000

12085000

11085000

4818000

5437000

-7000

-58000

-749000

-626000

-279000

-715000

-641000

75000

-641000

75000

7351000

9523000

-614000

24000

239000

24000

151000

64000

307000

20000

244000

43000

125000

4100000

3800000

926000

457000

503000

515000

3553000

3170000

6044000

3103000

2798000

5673000

118000

3200000

3800000

850000

P8Y5M1D

128000

36000

178000

-12000

64000

749000

718000

385000

360000

6765000

7482000

3993000

4434000

P9Y

P3Y

18000

15200

18000

5600

1303000

1597000

-72673000

-72600000

-72598000

6737000

180000

6530000

27000

113000

9413000

21000

9547000

The majority of the Company's revenue arrangements are service contracts that are complete within a year or less. There are a few contracts that range in duration between 1 and 3 years.

3205000

3872000

870000

1208000

131000

120000

0.0000

0.7264

0.0000

0.0039

1957682

1942264

15418

2.85

500

7500

9.85

10663000

2271658

2228326

43332

2276263

2235014

41249

3.23

3.24

2276263

2235014

41249

3.24

4.20

2.51

8.94

P0Y

P6Y0M0D

11810000

P4Y2M14D

P5Y0M0D

P4Y9M21D

11619538

12726728

12727888

1160

2238000

72924000

12000

-70698000

1728000

73055000

12000

-71339000

5318000

77978000

13000

-72673000

5513000

78098000

13000

-72598000

us-gaap:ServiceMember

2404000

2689000

178000

11619538

14231641

11619538

12727275

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;text-indent:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31, 2020</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets, net</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current portion of operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue was as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">April 30, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables represents disaggregated revenue for the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.6796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmacology services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personalized oncology services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total oncology services revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Payments</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was recognized as follows (table in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.836501901140686%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of oncology services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Black-Scholes assumptions used to calculate the fair value of options granted during the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:51.71102661596958%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average fair value of stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$9.85</font><font style="font-family:inherit;font-size:10pt;">. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> stock options granted during the three months ended July 31, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s stock options activity for the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> was a</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">s follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.62737642585552%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors<br clear="none"/>and<br clear="none"/>Employees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, April 30, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,228,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,271,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,663,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,235,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest as of July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,235,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable as of July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,957,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,810,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments due each fiscal year as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,851</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Being Evaluated</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Simplifying the Accounting for Income Taxes. The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC Topic 740 and removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years with early adoption permitted. We are currently assessing the impact of this update on our consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as small reporting companies. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases", (Topic 842), which required the Company to recognize lease assets and lease liabilities (related to leases previously classified as operating under previous U.S. GAAP) on its consolidated balance sheet for all leases in excess of one year in duration. The ASU was effective for the Company on May 1, 2019. The Company elected to adopt ASU 2016-02 using the modified retrospective method and, therefore, have not recast comparative periods presented in its unaudited consolidated financial statements. As permitted under ASU 2016-02, the Company elected to account for the non-lease components together with the lease components as a single lease component. The Company recorded an operating lease right-of-use ("ROU") asset of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of deferred rent of </font><font style="font-family:inherit;font-size:10pt;">$900,000</font><font style="font-family:inherit;font-size:10pt;"> and an operating lease liability of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of May 1, 2019. See Note 8 of this Form 10-Q for additional information and required disclosures. Under Topic 842, the Company determined if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. This ASU was effective for and adopted by the Company on May 1, 2020. The adoption had no material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee share based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance was effective for the Company on May 1, 2019. The Company adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (table in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31, <br clear="none"/>2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">April 30, <br clear="none"/>2020</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable and unbilled services were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">April 30, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,689</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable and unbilled services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects the total potential share-based instruments outstanding at </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> that could have an effect on the future computation of dilution per common share, had their effect not been anti-dilutive:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.0625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,374,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,669,773</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,044,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net (loss) income per share computation (dollars in thousands):</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average common shares – basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,727,275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per share computation:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) available to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,727,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incremental shares from assumed exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,504,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted weighted average share – diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,231,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was recognized as follows (table in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.836501901140686%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of oncology services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s stock options activity for the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> was a</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">s follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.62737642585552%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors<br clear="none"/>and<br clear="none"/>Employees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, April 30, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,228,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,271,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,663,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,235,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest as of July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,235,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable as of July 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,957,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,810,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Black-Scholes assumptions used to calculate the fair value of options granted during the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:51.71102661596958%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.64%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents. As of </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and April 30, 2020 the Company had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> cash equivalents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services. For the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company had net income of approximately </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;"> and cash used in operations of </font><font style="font-family:inherit;font-size:10pt;">$715,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$72.6 million</font><font style="font-family:inherit;font-size:10pt;">, working capital of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and cash of </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;">. We believe that our cash on hand, together with expected net positive cash used in operations for fiscal year 2021, are adequate to fund operations through at least 12 months from the filing of this 10-Q. However, should our revenue expectations not materialize, we believe we have cost reduction strategies that could be implemented without disrupting the business or restructuring the Company. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective May 1, 2019, the Company accounts for its leases under Accounting Standards Codification ("ASC") Topic 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease, if applicable, or the Company’s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income or loss per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing the net income or loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s common stock purchase warrants and stock options. </font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>July 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net (loss) income per share computation (dollars in thousands):</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average common shares – basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,727,275</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per share computation:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) available to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,727,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incremental shares from assumed exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,504,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted weighted average share – diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,231,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,619,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects the total potential share-based instruments outstanding at </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> that could have an effect on the future computation of dilution per common share, had their effect not been anti-dilutive:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.0625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">July 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,374,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,669,773</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,276,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,044,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.  In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient earnings history, a valuation allowance is established. Our ability to utilize net operating losses (“NOL”) carryforwards to offset our future taxable income would be limited if we have undergone or were to undergo an “ownership change” within the meaning of Section 382 of the Internal Revenue Code (the “IRC”). The Company adjusts the valuation allowance in the period management determines it is more likely than not that deferred tax assets will or will not be realized.  Changes in valuation allowances from period to period are included in the tax provision in the period of change.  As of </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 30, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements.  Tax positions include, but are not limited to, the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An allocation or shift of income between taxing jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The characterization of income or a decision to exclude reportable taxable income in a tax return; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A decision to classify a transaction, entity or other position in a tax return as tax exempt.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reflects tax benefits only if it is more likely than not that the Company will be able to sustain the tax position, based on its technical merits.  If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized.  The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$178,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$178,000</font><font style="font-family:inherit;font-size:10pt;"> of liabilities related to uncertain tax positions relative to one of its foreign operations as of </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 30, 2020</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at </font><font style="font-family:inherit;font-size:10pt;">July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 30, 2020</font><font style="font-family:inherit;font-size:10pt;">, and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes for the </font><font style="font-family:inherit;font-size:10pt;">three months ended July 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, mainly attributable to taxable income earned in Israel. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All revenue is generated from contracts with customers. The Company's arrangements are service type contracts that mainly have a duration of less than a year. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pharmacology Study, POS Services and Other Services</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At contract inception, the Company assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. The Company's fixed-fee arrangements for oncology services are considered a single performance obligation because the Company provides a highly-integrated service.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue over time using a progress-based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Revenue is recognized for the single performance obligation over time due to the Company's right to payment for work performed to date and the performance does not create an asset with an alternative use. The Company recognizes revenue as portions of the overall performance obligation are completed as this best depicts the progress of the performance obligation.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Consideration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as the success of the initial performance obligation. Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Receivables, Unbilled Services and Deferred Revenue</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. In general, the Company's intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from the timing of payment terms and when an input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Being Evaluated</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Simplifying the Accounting for Income Taxes. The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC Topic 740 and removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years with early adoption permitted. We are currently assessing the impact of this update on our consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses". This update requires immediate recognition of management’s estimates of current expected credit losses ("CECL"). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as small reporting companies. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases", (Topic 842), which required the Company to recognize lease assets and lease liabilities (related to leases previously classified as operating under previous U.S. GAAP) on its consolidated balance sheet for all leases in excess of one year in duration. The ASU was effective for the Company on May 1, 2019. The Company elected to adopt ASU 2016-02 using the modified retrospective method and, therefore, have not recast comparative periods presented in its unaudited consolidated financial statements. As permitted under ASU 2016-02, the Company elected to account for the non-lease components together with the lease components as a single lease component. The Company recorded an operating lease right-of-use ("ROU") asset of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of deferred rent of </font><font style="font-family:inherit;font-size:10pt;">$900,000</font><font style="font-family:inherit;font-size:10pt;"> and an operating lease liability of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of May 1, 2019. See Note 8 of this Form 10-Q for additional information and required disclosures. Under Topic 842, the Company determined if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, which amends ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement ("CCA") that is a service contract. This update aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. This ASU was effective for and adopted by the Company on May 1, 2020. The adoption had no material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting". This ASU expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee share based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance was effective for the Company on May 1, 2019. The Company adopted this new rule beginning with its financial reporting for the quarter ended January 31, 2019. The adoption had no material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 11, 2019, the FASB issued ASU 2019-08 which clarifies the accounting for share-based payments issued as consideration payable to a customer in accordance with ASC 606. Under the ASU, entities apply the guidance in ASC 718 to measure and classify share-based payments issued to a customer that are not in exchange for a distinct good or service (i.e., share-based sales incentives). The ASU was effective for the Company on May 1, 2020 and the adoption had no material impact on our consolidated financial statements.</font></div></div>

EX-101.SCH 6 csbr-20200731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Leases - ROU Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization, Use of Estimates and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Share-Based Payments - Allocation of Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Share-Based Payments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Share-Based Payments - Valuation Assumptions for Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Significant Accounting Policies - Calculation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2202202 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Significant Accounting Policies - Summary of Potentially Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 csbr-20200731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 csbr-20200731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 csbr-20200731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Payment Arrangement [Abstract] Weighted-average grant date fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Receivables [Abstract] Summary of accounts receivable, unbilled services, and advanced billings Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Summary of advanced billings Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Property and equipment, net Property, Plant and Equipment, Net Other long-term assets Other Assets, Noncurrent Goodwill Goodwill Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Current portion of finance lease Finance Lease, Liability, Current Current portion of operating lease liabilities Operating Lease, Liability, Current Deferred revenue Contract with Customer, Liability, Current Total current liabilities Liabilities, Current Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $.001 par value; 200,000,000 shares authorized; 12,727,888 and 12,726,728 shares issued and outstanding as of July 31, 2020 and April 30, 2020, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Property, Plant and Equipment [Abstract] Furniture and fixtures Furniture and Fixtures, Gross Computer equipment and software Capitalized Computer Software, Gross Laboratory equipment Machinery and Equipment, Gross Assets in progress Assets in Progress, Gross Assets in Progress, Gross Leasehold improvements Leasehold Improvements, Gross Total property and equipment Property, Plant and Equipment, Gross Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General and administrative General and Administrative Expense [Member] Sales and marketing Selling and Marketing Expense [Member] Research and development Research and Development Expense [Member] Cost of oncology services Cost of Sales [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation expense Share-based Payment Arrangement, Expense Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Gain on termination of operating lease Gain (Loss) on Termination of Lease Operating lease right-of use assets Increase (Decrease) In Operating Lease, Right Of Use Assets Increase (Decrease) In Operating Lease, Right Of Use Assets Provision for doubtful accounts Reversal of Provision for Doubtful Accounts Reversal of Provision for Doubtful Accounts Changes in operating assets and liabilities: Increase (Decrease) in Operating Liabilities [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Operating lease liabilities Increase (Decrease) In Operating Lease Liabilities Increase (Decrease) In Operating Lease Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds From Refund Of Security Deposit Proceeds From Refund Of Security Deposit Proceeds From Refund Of Security Deposit Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Finance lease payments Finance Lease, Principal Payments Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Decrease in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash at end of period Non-cash investing activities: Other Noncash Investing and Financing Items [Abstract] Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Allocation of Share Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Valuation Assumptions for Stock Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Accounts receivable Accounts Receivable, before Allowance for Credit Loss Unbilled services Unbilled Contracts Receivable Total accounts receivable and unbilled services Accounts Receivable, before Allowance for Credit Loss, Current Less allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Total accounts receivable, net Cash equivalents Cash Equivalents, at Carrying Value Net cash provided by (used in) operating activities Accumulated deficit Working capital deficit Working Capital (Deficit) Amount of reporting entity working capital (deficit) has reported. Cash and cash equivalents Unrecognized tax benefits Unrecognized Tax Benefits Provision for income taxes Income Tax Expense (Benefit) Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update [Axis] Accounting Standards Update [Axis] Accounting Standards Update [Domain] Accounting Standards Update [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Deferred rent Advance Rent Operating lease liability Operating Lease, Liability Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Board Member One Board Member One [Member] Board Member One [Member] Board Member Two Board Member Two [Member] Board Member Two [Member] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Board Member Board of Directors Chairman [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related party transaction, amounts of transaction Related Party Transaction, Amounts of Transaction Due to related parties Due to Related Parties Revenue from Contract with Customer [Abstract] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Pharmacology services Pharmacology Services [Member] Pharmacology Services [Member] Personalized oncology services Personalized Oncology Services [Member] Personalized Oncology Services [Member] Other Product and Service, Other [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Description of timing Revenue, Performance Obligation, Description of Timing Oncology services revenue Revenue from Contract with Customer, Excluding Assessed Tax Leases [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2022 Lessee, Operating Lease, Liability, to be Paid, Year One 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Total Lessee, Operating Lease, Liability, to be Paid Basic loss per share computation Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net income (loss) attributable to common stockholders Weighted Average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Income (loss) available to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Incremental shares from assumed exercise of warrants and stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Adjusted weighted average share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted net income (loss) per share (in usd per share) Earnings Per Share, Diluted Expected term in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rates Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Grantee Status [Axis] Grantee Status [Axis] Grantee Status [Domain] Grantee Status [Domain] Directors and Employees Share-based Payment Arrangement, Employee [Member] Non- Employees Share-based Payment Arrangement, Nonemployee [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Canceled (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, ending balance (in shares) Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in usd per share) Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, ending balance (in usd per share) Vested and expected to vest (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price EX-101.PRE 10 csbr-20200731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jul. 31, 2020	Sep. 04, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	0000771856
Current Fiscal Year End Date	--04-30
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		12,727,888

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 31, 2020	Apr. 30, 2020
Current assets:
Cash	$ 6,943	$ 8,342
Accounts receivable, net	5,039	4,770
Prepaid expenses and other current assets	360	385
Total current assets	12,342	13,497
Operating lease right-of-use assets, net	5,673	2,798
Property and equipment, net	4,434	3,993
Other long-term assets	36	128
Goodwill	335	335
Total assets	22,820	20,751
Current liabilities:
Accounts payable	2,675	3,140
Accrued liabilities	2,154	2,502
Current portion of finance lease	72	125
Current portion of operating lease liabilities	515	503
Deferred revenue	5,669	5,815
Total current liabilities	11,085	12,085
Non-current operating lease liabilities	6,044	3,170
Other non-current liabilities	178	178
Total liabilities	17,307	15,433
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 12,727,888 and 12,726,728 shares issued and outstanding as of July 31, 2020 and April 30, 2020, respectively	13	13
Additional paid-in capital	78,098	77,978
Accumulated deficit	(72,598)	(72,673)
Total stockholders’ equity	5,513	5,318
Total liabilities and stockholders’ equity	$ 22,820	$ 20,751

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Jul. 31, 2020	Apr. 30, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	12,727,888	12,726,728
Common stock, shares outstanding (in shares)	12,727,888	12,726,728

XML 14 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Income Statement [Abstract]
Oncology services revenue	$ 9,547	$ 6,737
Costs and operating expenses:
Cost of oncology services	5,336	3,752
Research and development	1,597	1,303
Sales and marketing	1,208	870
General and administrative	1,382	1,426
Total costs and operating expenses	9,523	7,351
Income (loss) from operations	24	(614)
Other income (expense):
Other income (expense)	64	(12)
Income (loss) before provision for income taxes	88	(626)
Provision for income taxes	13	15
Net income (loss)	$ 75	$ (641)
Net income (loss) per common share outstanding
Net income (loss) per common share outstanding, basic (in dollars per share)	$ 0.01	$ (0.06)
Net income (loss) per common share outstanding, diluted (in dollars per share)	$ 0.01	$ (0.06)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic (in shares)	12,727,275	11,619,538
Weighted average common shares outstanding, diluted (in shares)	14,231,641	11,619,538
Revenue, Product and Service [Extensible List]	us-gaap:ServiceMember
Cost, Product and Service [Extensible List]	us-gaap:ServiceMember

XML 15 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (shares) at Apr. 30, 2019		11,619,538
Beginning balance at Apr. 30, 2019	$ 2,238	$ 12	$ 72,924	$ (70,698)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	131		131
Net income (loss)	(641)			(641)
Ending balance (shares) at Jul. 31, 2019		11,619,538
Ending balance at Jul. 31, 2019	1,728	$ 12	73,055	(71,339)
Beginning balance (shares) at Apr. 30, 2020		12,726,728
Beginning balance at Apr. 30, 2020	5,318	$ 13	77,978	(72,673)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 120		120
Issuance of common stock on exercise of stock options (in shares)	1,160
Issuance of common stock on exercise of stock options	$ 0
Net income (loss)	75			75
Ending balance (shares) at Jul. 31, 2020		12,727,888
Ending balance at Jul. 31, 2020	$ 5,513	$ 13	$ 78,098	$ (72,598)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Operating activities:
Net income (loss)	$ 75	$ (641)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	120	131
Depreciation and amortization expense	277	182
Gain on termination of operating lease	(75)	0
Operating lease right-of use assets	(67)	98
Provision for doubtful accounts	(6)	6
Changes in operating assets and liabilities:
Accounts receivable	(263)	480
Prepaid expenses and other current assets	25	52
Accounts payable	(465)	(82)
Accrued liabilities	(348)	(410)
Other non-current liabilities	1	0
Operating lease liabilities	157	(42)
Deferred revenue	(146)	(53)
Net cash used in operating activities	(715)	(279)
Investing activities:
Purchase of property and equipment	(718)	(749)
Proceeds From Refund Of Security Deposit	92	0
Net cash used in investing activities	(626)	(749)
Financing activities:
Finance lease payments	(58)	(7)
Net cash used in financing activities	(58)	(7)
Decrease in cash	(1,399)	(1,035)
Cash at beginning of period	8,342	3,237
Cash at end of period	6,943	2,202
Non-cash investing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 3,872	$ 3,205

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization, Use of Estimates and Basis of Presentation	3 Months Ended
	Jul. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Use of Estimates and Basis of Presentation	Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the “Company”) is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. Utilizing the TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well characterized "Patient Derived XenoGrafts" (PDX) models, the Company offers multiple services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs. The Company has two operating subsidiaries: Champions Oncology (Israel), Limited and Champions Biotechnology U.K., Limited. For the three months ended July 31, 2020 and 2019, there were no revenues earned by these subsidiaries. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, or GAAP, has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2020, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2020. The results of operations for the interim periods are not necessarily indicative of the results of operations for a full fiscal year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Jul. 31, 2020

Accounting Policies [Abstract]

Significant Accounting Policies

Cash and Cash Equivalents

Liquidity

Leases

Earnings Per Share



	Three Months Ended July 31,
	2020		2019
Basic and diluted net (loss) income per share computation (dollars in thousands):
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Weighted Average common shares – basic	12,727,275		11,619,538
Basic net income (loss) per share	$	0.01	$	(0.06	)

Diluted income (loss) per share computation:
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Income (loss) available to common stockholders	$	75	$	(641	)

Weighted Average common shares	12,727,275		11,619,538
Incremental shares from assumed exercise of stock options	1,504,366		—
Adjusted weighted average share – diluted	14,231,641		11,619,538

Diluted net income (loss) per share	$	0.01	$	(0.06	)



	July 31,
	2020	2019
Stock options	2,276,263	2,374,875
Warrants	—	1,669,773

Total common stock equivalents	2,276,263	4,044,648

Income Taxes


•	An allocation or shift of income between taxing jurisdictions;


•	The characterization of income or a decision to exclude reportable taxable income in a tax return; or


•	A decision to classify a transaction, entity or other position in a tax return as tax exempt.

The Company reflects tax benefits only if it is more likely than not that the Company will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company recorded $178,000 and $178,000 of liabilities related to uncertain tax positions relative to one of its foreign operations as of July 31, 2020 and April 30, 2020, respectively.

The provision for income taxes for the three months ended July 31, 2020 and 2019 was $13,000 and $15,000, respectively, mainly attributable to taxable income earned in Israel.

Revenue Recognition

Pharmacology Study, POS Services and Other Services

Variable Consideration

Trade Receivables, Unbilled Services and Deferred Revenue

Deferred revenue consists of unearned payments received in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the deferred revenue balance is reduced by the amount of the revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.

Accounting Pronouncements Being Evaluated

Recently Adopted Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Accounts Receivable, Unbilled Services and Deferred Revenue

3 Months Ended

Jul. 31, 2020

Receivables [Abstract]

Accounts Receivable, Unbilled Services and Deferred Revenue

Accounts receivable and unbilled services were as follows (in thousands):



	July 31, 2020			April 30, 2020
Accounts receivable	$	2,633		$	2,655
Unbilled services	2,689			2,404
Total accounts receivable and unbilled services	5,322			5,059
Less allowance for doubtful accounts	(283		)	(289		)
Total accounts receivable, net	$	5,039		$	4,770

Deferred revenue was as follows (in thousands):



	July 31, 2020		April 30, 2020
Deferred revenue	$	5,669	$	5,815

Deferred revenue is shown as a current liability on the Company's condensed consolidated balance sheet.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers

3 Months Ended

Jul. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Oncology Services Revenue

Other revenue represents services provided to the pharmaceutical and biotechnology companies. The Company does not consider these services part of their core product offerings.

The following tables represents disaggregated revenue for the three months ended July 31, 2020 and 2019:



	Three Months Ended July 31,
	2020		2019
Pharmacology services	$	9,413	$	6,530
Personalized oncology services	113		180
Other	21		27
Total oncology services revenue	$	9,547	$	6,737

Contract Balances

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Jul. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment



	July 31, 2020			April 30, 2020
Furniture and fixtures	$	238		$	180
Computer equipment and software	1,689			1,209
Laboratory equipment	5,437			4,818
Assets in progress	114			554
Leasehold improvements	4			4

Total property and equipment	7,482			6,765
Less: Accumulated depreciation	(3,048		)	(2,772		)

Property and equipment, net	$	4,434		$	3,993

Depreciation and amortization expense, excluding expense recorded under the finance lease, was $224,000 and $145,000 for the three months ended July 31, 2020 and 2019, respectively.

Finance Lease

In July 2018, the Company entered into a second finance lease for laboratory equipment. The lease had total costs of approximately $266,000, inclusive of interest and taxes, with a monthly payment of approximately $11,000. Although the lease was originally due to mature in July 2020, the Company decided to pay the outstanding balance on February 1, 2019. As a result, the entire outstanding balance of the lease was nil as of July 31, 2019.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Share-Based Payments

3 Months Ended

Jul. 31, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Payments

Stock-based compensation expense was recognized as follows (table in thousands):



	Three Months Ended July 31,
	2020		2019
General and administrative	$	47	$	132
Sales and marketing	48		22
Research and development	4		3
Cost of oncology services	21		(26		)
Total stock-based compensation expense	$	120	$	131

Stock Option Grants

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2020 and 2019 were as follows:



	Three Months Ended July 31,
	2020	2019
Expected term in years	6	—
Risk-free interest rates	0.39%	—%
Volatility	72.64%	—%
Dividend yield	—%	—%

The weighted average fair value of stock options granted during the three months ended July 31, 2020 was $9.85. There was no stock options granted during the three months ended July 31, 2019.

The Company’s stock options activity for the three months ended July 31, 2020 was as follows:



	Directors and Employees		Non- Employees		Total		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2020	2,228,326		43,332		2,271,658		$	3.23	5.0	$	10,663,000
Granted	7,500		—		7,500		8.94		9.85
Exercised			(1,160	)	(1,160	)	4.20
Forfeited	(500	)	—		(500	)	2.51
Canceled	(312	)	(923	)	(1,235	)	4.95
Expired	—		—		—

Outstanding, July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Vested and expected to vest as of July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Exercisable as of July 31, 2020	1,942,264		15,418		1,957,682		2.85		4.21	$	11,810,000

XML 23 R13.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Jul. 31, 2020

Leases [Abstract]

Leases

The Company accounts for its leases under ASU 2016-02, "Leases", Topic 842.

Operating Leases

The Company leases the following facilities:


•	One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2021. The Company recognized $20,000 and $24,000 of rental costs relative to this lease for the three months ended July 31, 2020 and 2019, respectively.


•	1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed this lease on January 11, 2017. The operating commencement date was August 11, 2017. This lease originally expired in August 2028.


◦	On March 30, 2020, the Company executed the first amendment to this lease to expand the existing premises at 1330 Piccard Drive, Suite 025 ("Expansion Premises") to add on Suites 050 and 104. This amendment also extended the current lease term by six months. The Expansion Premises operating lease commencement date was June 1, 2020 and, under the amendment, both leases expire February 28, 2029.

◦


◦	Upon the Expansion Premises operating lease commencement date (June 1, 2020), the Company recognized an operating ROU asset and related operating lease liability for Suites 050 and 104 of $3.8 million, each, respectively.


◦	For the leases related to Piccard Drive, the Company recognized $244,000 and $151,000 of rental expense for the three months ended July 31, 2020 and 2019.

•

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):



	July 31, 2020		July 31, 2019
Operating lease right-of-use assets, net	$	5,673	$	3,103
Current portion of operating lease liabilities	515		457
Non-current portion of operating lease liabilities	6,044		3,553

As of July 31, 2020, the weighted average remaining operating lease term and the weighted average discount rate were 8.42 years and 6.10%, respectively.

Future minimum lease payments due each fiscal year as follows (in thousands):



2021	$	1,117
2022	1,851
2023	1,818
2024	1,844
2025	1,867
Thereafter	7,268
Total	$	15,765

Refer to Note 5, Property and Equipment, for more information on financing leases.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions	3 Months Ended
Related Party Transactions	Jul. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties. Consulting Services During the three months ended July 31, 2020 and 2019, the Company paid an affiliate of a board member $18,000 for consulting services unrelated to his duty as a board member. During the three months ended July 31, 2020 and 2019, the Company paid an affiliate of another board member $5,600 and 15,200, respectively, for consulting services unrelated to their duties as a board member. As of July 31, 2020, $7,400 was due to these related parties.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Jul. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Risks and uncertainties related to Covid-19 In December 2019, a novel strain of coronavirus, COVID-19, was first identified in Wuhan, China. This virus continues to spread globally and, as of July 2020, has spread to over 200 countries, including the United States. The spread of COVID-19 from China to other countries has resulted in the World Health Organization declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Employers are also required to increase, as much as possible, the capacity and arrangement for employees to work remotely. In addition, on March 11, 2020, the President of the United States issued a proclamation to restrict travel to the United States from foreign nationals who have recently been in certain European and Latin American countries. Although, to date, these restrictions have not impacted our operations, the effect on our business, from the spread of COVID-19 and the actions implemented by the governments of the United States and elsewhere across the globe, may worsen over time. Any outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations. These could include disruptions or restrictions on our ability to travel, pursue partnerships and other business transactions, receive shipments of biologic materials, as well as be impacted by the temporary closure of the facilities of suppliers. The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver supplies to us on a timely basis. In addition, health professionals may reduce staffing and reduce or postpone meetings with clients in response to the spread of an infectious disease. Though we have not yet experienced such events, if they would occur, they could result in a period of business disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. However, as of the date of this Form 10-Q, we have not experienced a material adverse effect on our business nor the need for reduction in our work force; and, currently, and we do not expect any material impact on our long-term activity. The extent to which COVID-19 impacts our business will depend on future developments which are highly uncertain and cannot be predicted, including, but not limited to, new information which may emerge concerning the increased severity of COVID-19, the actions to contain COVID-19, or treat its impact. Legal Matters The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Jul. 31, 2020

Accounting Policies [Abstract]

Cash and Cash Equivalents

The Company considers only those investments which are highly liquid, readily convertible to cash, and with original maturities of three months or less to be cash equivalents.

Leases

Earnings Per Share

Income Taxes


•	An allocation or shift of income between taxing jurisdictions;


•	The characterization of income or a decision to exclude reportable taxable income in a tax return; or


•	A decision to classify a transaction, entity or other position in a tax return as tax exempt.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense.

Revenue Recognition

Pharmacology Study, POS Services and Other Services

Variable Consideration

Trade Receivables, Unbilled Services and Deferred Revenue

Accounting Pronouncements Being Evaluated/Recently Adopted Accounting Pronouncements

Accounting Pronouncements Being Evaluated

Recently Adopted Accounting Pronouncements

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

+ Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

3 Months Ended

Jul. 31, 2020

Accounting Policies [Abstract]

Summary of the Calculation of Earnings per Share, Basic and Diluted



	Three Months Ended July 31,
	2020		2019
Basic and diluted net (loss) income per share computation (dollars in thousands):
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Weighted Average common shares – basic	12,727,275		11,619,538
Basic net income (loss) per share	$	0.01	$	(0.06	)

Diluted income (loss) per share computation:
Net income (loss) attributable to common stockholders	$	75	$	(641	)
Income (loss) available to common stockholders	$	75	$	(641	)

Weighted Average common shares	12,727,275		11,619,538
Incremental shares from assumed exercise of stock options	1,504,366		—
Adjusted weighted average share – diluted	14,231,641		11,619,538

Diluted net income (loss) per share	$	0.01	$	(0.06	)

Summary of Antidilutive Securities Excluded from Earnings Per Share Calculations



	July 31,
	2020	2019
Stock options	2,276,263	2,374,875
Warrants	—	1,669,773

Total common stock equivalents	2,276,263	4,044,648

XML 28 R18.htm IDEA: XBRL DOCUMENT

Accounts Receivable, Unbilled Services and Deferred Revenue (Tables)

3 Months Ended

Jul. 31, 2020

Receivables [Abstract]

Summary of accounts receivable, unbilled services, and advanced billings

Accounts receivable and unbilled services were as follows (in thousands):



	July 31, 2020			April 30, 2020
Accounts receivable	$	2,633		$	2,655
Unbilled services	2,689			2,404
Total accounts receivable and unbilled services	5,322			5,059
Less allowance for doubtful accounts	(283		)	(289		)
Total accounts receivable, net	$	5,039		$	4,770

Summary of advanced billings

Deferred revenue was as follows (in thousands):



	July 31, 2020		April 30, 2020
Deferred revenue	$	5,669	$	5,815

XML 29 R19.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers (Tables)

3 Months Ended

Jul. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following tables represents disaggregated revenue for the three months ended July 31, 2020 and 2019:



	Three Months Ended July 31,
	2020		2019
Pharmacology services	$	9,413	$	6,530
Personalized oncology services	113		180
Other	21		27
Total oncology services revenue	$	9,547	$	6,737

XML 30 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Jul. 31, 2020

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following (table in thousands):



	July 31, 2020			April 30, 2020
Furniture and fixtures	$	238		$	180
Computer equipment and software	1,689			1,209
Laboratory equipment	5,437			4,818
Assets in progress	114			554
Leasehold improvements	4			4

Total property and equipment	7,482			6,765
Less: Accumulated depreciation	(3,048		)	(2,772		)

Property and equipment, net	$	4,434		$	3,993

XML 31 R21.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Tables)

3 Months Ended

Jul. 31, 2020

Share-based Payment Arrangement [Abstract]

Allocation of Share Based Compensation Expense

Stock-based compensation expense was recognized as follows (table in thousands):



	Three Months Ended July 31,
	2020		2019
General and administrative	$	47	$	132
Sales and marketing	48		22
Research and development	4		3
Cost of oncology services	21		(26		)
Total stock-based compensation expense	$	120	$	131

Valuation Assumptions for Stock Options

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2020 and 2019 were as follows:



	Three Months Ended July 31,
	2020	2019
Expected term in years	6	—
Risk-free interest rates	0.39%	—%
Volatility	72.64%	—%
Dividend yield	—%	—%

Summary of Stock Option Activity

The Company’s stock options activity for the three months ended July 31, 2020 was as follows:



	Directors and Employees		Non- Employees		Total		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2020	2,228,326		43,332		2,271,658		$	3.23	5.0	$	10,663,000
Granted	7,500		—		7,500		8.94		9.85
Exercised			(1,160	)	(1,160	)	4.20
Forfeited	(500	)	—		(500	)	2.51
Canceled	(312	)	(923	)	(1,235	)	4.95
Expired	—		—		—

Outstanding, July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Vested and expected to vest as of July 31, 2020	2,235,014		41,249		2,276,263		3.24		4.81

Exercisable as of July 31, 2020	1,942,264		15,418		1,957,682		2.85		4.21	$	11,810,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Jul. 31, 2020

Leases [Abstract]

Assets and Liabilities

ROU assets and lease liabilities related to our current operating leases are as follows (in thousands):



	July 31, 2020		July 31, 2019
Operating lease right-of-use assets, net	$	5,673	$	3,103
Current portion of operating lease liabilities	515		457
Non-current portion of operating lease liabilities	6,044		3,553

Future Operating Lease Payments

Future minimum lease payments due each fiscal year as follows (in thousands):



2021	$	1,117
2022	1,851
2023	1,818
2024	1,844
2025	1,867
Thereafter	7,268
Total	$	15,765

XML 33 R23.htm IDEA: XBRL DOCUMENT

Organization, Use of Estimates and Basis of Presentation (Details)	3 Months Ended
	Jul. 31, 2020 subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating subsidiaries	2

XML 34 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Apr. 30, 2020	May 01, 2019
Accounting Policies [Abstract]
Cash equivalents	$ 0		$ 0
Net income (loss)	75,000	$ (641,000)
Net cash provided by (used in) operating activities	(715,000)	(279,000)
Accumulated deficit	72,598,000		72,673,000
Working capital deficit	1,300,000
Cash and cash equivalents	6,943,000		8,342,000
Unrecognized tax benefits	178,000		178,000
Provision for income taxes	13,000	15,000
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets, net	$ 5,673,000	$ 3,103,000	$ 2,798,000
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets, net				$ 3,200,000
Deferred rent				900,000
Operating lease liability				$ 4,100,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Basic loss per share computation
Net income (loss) attributable to common stockholders	$ 75	$ (641)
Weighted Average common shares - basic (in shares)	12,727,275	11,619,538
Basic net income (loss) per share (in dollars per share)	$ 0.01	$ (0.06)
Income (loss) available to common stockholders	$ 75	$ (641)
Incremental shares from assumed exercise of warrants and stock options (in shares)	1,504,366	0
Adjusted weighted average share - diluted (in shares)	14,231,641	11,619,538
Diluted net income (loss) per share (in usd per share)	$ 0.01	$ (0.06)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Potentially Antidilutive Securities (Details) - shares	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents (in shares)	2,276,263	4,044,648
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents (in shares)	2,276,263	2,374,875
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents (in shares)	0	1,669,773

XML 37 R27.htm IDEA: XBRL DOCUMENT

Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Apr. 30, 2020
Receivables [Abstract]
Accounts receivable	$ 2,633	$ 2,655
Unbilled services	2,689	2,404
Total accounts receivable and unbilled services	5,322	5,059
Less allowance for doubtful accounts	(283)	(289)
Total accounts receivable, net	$ 5,039	$ 4,770

XML 38 R28.htm IDEA: XBRL DOCUMENT

Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Apr. 30, 2020
Receivables [Abstract]
Deferred revenue	$ 5,669	$ 5,815

XML 39 R29.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disaggregation of Revenue [Line Items]
Description of timing	The majority of the Company's revenue arrangements are service contracts that are complete within a year or less. There are a few contracts that range in duration between 1 and 3 years.
Oncology services revenue	$ 9,547	$ 6,737
Pharmacology services
Disaggregation of Revenue [Line Items]
Oncology services revenue	9,413	6,530
Personalized oncology services
Disaggregation of Revenue [Line Items]
Oncology services revenue	113	180
Other
Disaggregation of Revenue [Line Items]
Oncology services revenue	$ 21	$ 27

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Property and Equipment - Narrative (Details) - USD ($)	1 Months Ended		3 Months Ended			61 Months Ended
Property and Equipment - Narrative (Details) - USD ($)	Dec. 31, 2019	Jul. 31, 2018	Jul. 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Nov. 30, 2019	Apr. 30, 2020
Property, Plant and Equipment [Line Items]
Depreciation			$ 224,000		$ 145,000
Assets under finance lease			343,000				$ 366,000
Finance lease costs	$ 231,000	$ 266,000				$ 149,000
Future minimum lease payments remaining	77,000		58,000	$ 2,000	7,000
Finance leases monthly payments	$ 19,000	$ 11,000
Finance lease, liability					0
Present value of minimum future obligations interest rate	4.75%
Finance lease, amortization			53,100
Finance Leased Assets
Property, Plant and Equipment [Line Items]
Depreciation			$ 53,000		$ 37,000
Minimum
Property, Plant and Equipment [Line Items]
Useful lives			3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful lives			9 years

XML 41 R31.htm IDEA: XBRL DOCUMENT

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Apr. 30, 2020
Property, Plant and Equipment [Abstract]
Furniture and fixtures	$ 238	$ 180
Computer equipment and software	1,689	1,209
Laboratory equipment	5,437	4,818
Assets in progress	114	554
Leasehold improvements	4	4
Total property and equipment	7,482	6,765
Less: Accumulated depreciation	(3,048)	(2,772)
Property and equipment, net	$ 4,434	$ 3,993

XML 42 R32.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Narrative (Details) - $ / shares	3 Months Ended
Share-Based Payments - Narrative (Details) - $ / shares	Jul. 31, 2020	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Weighted-average grant date fair value (in usd per share)	$ 9.85
Granted (in shares)	7,500	0

XML 43 R33.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Allocation of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 120	$ 131
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	47	132
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	48	22
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	4	3
Cost of oncology services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 21	$ (26)

XML 44 R34.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Expected term in years	6 years	0 years
Risk-free interest rates	0.39%	0.00%
Volatility	72.64%	0.00%
Dividend yield	0.00%	0.00%

XML 45 R35.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Apr. 30, 2020
Total
Outstanding, beginning balance (in shares)	2,271,658
Granted (in shares)	7,500	0
Exercised (in shares)	(1,160)
Forfeited (in shares)	(500)
Canceled (in shares)	(1,235)
Expired (in shares)	0
Outstanding, ending balance (in shares)	2,276,263
Vested and expected to vest (in shares)	2,276,263
Exercisable (in shares)	1,957,682
Weighted Average Exercise Price
Outstanding, beginning balance (in usd per share)	$ 3.23
Granted (in usd per share)	8.94
Exercised (in usd per share)	4.20
Forfeited (in usd per share)	2.51
Canceled (in usd per share)	4.95
Expired (in usd per share)
Outstanding, ending balance (in usd per share)	3.24
Vested and expected to vest (in usd per share)	3.24
Exercisable (in usd per share)	$ 2.85
Weighted Average Remaining Contractual Term, Outstanding (in years)	4 years 9 months 21 days		5 years
Weighted Average Remaining Contractual Term, Outstanding, Granted (in years)	9 years 9 months 36 days
Weighted Average Remaining Contractual Life, Vested and expected to vest (in years)	4 years 9 months 21 days
Weighted Average Remaining Contractual Life, Exercisable (in years)	4 years 2 months 14 days
Aggregate Intrinsic Value, Outstanding				$ 10,663
Aggregate Intrinsic Value, Vested and expected to vest
Aggregate Intrinsic Value, Exercisable	$ 11,810
Directors and Employees
Total
Outstanding, beginning balance (in shares)	2,228,326
Granted (in shares)	7,500
Exercised (in shares)
Forfeited (in shares)	(500)
Canceled (in shares)	(312)
Expired (in shares)	0
Outstanding, ending balance (in shares)	2,235,014
Vested and expected to vest (in shares)	2,235,014
Exercisable (in shares)	1,942,264
Non- Employees
Total
Outstanding, beginning balance (in shares)	43,332
Granted (in shares)	0
Exercised (in shares)	(1,160)
Forfeited (in shares)	0
Canceled (in shares)	(923)
Expired (in shares)	0
Outstanding, ending balance (in shares)	41,249
Vested and expected to vest (in shares)	41,249
Exercisable (in shares)	15,418

XML 46 R36.htm IDEA: XBRL DOCUMENT

Leases (Details) - USD ($) $ in Thousands		3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jul. 31, 2020	Jul. 31, 2019	Jun. 01, 2020	Apr. 30, 2020	May 01, 2019
Lessee, Lease, Description [Line Items]
Operating leases, rent expense		$ 307	$ 239
Operating lease right-of-use assets, net		5,673	3,103		$ 2,798
Gain (loss) on termination of lease		$ 75	0
Weighted average remaining lease term		8 years 5 months 1 day
Discount rate						6.10%
Corporate Headquarters
Lessee, Lease, Description [Line Items]
Operating leases, rent expense		$ 20	24
Rockville, MD
Lessee, Lease, Description [Line Items]
Operating leases, rent expense		244	151
Operating lease right-of-use assets, net		118		$ 3,800
Operating lease liability		125		$ 3,800
Incremental rent expense		8
Rockville, MD New Location
Lessee, Lease, Description [Line Items]
Operating leases, rent expense		$ 43	$ 64
Operating lease right-of-use assets, net	$ 850
Operating lease liability	926
Gain (loss) on termination of lease	$ 76

XML 47 R37.htm IDEA: XBRL DOCUMENT

Leases - ROU Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Apr. 30, 2020	Jul. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets, net	$ 5,673	$ 2,798	$ 3,103
Current portion of operating lease liabilities	515	503	457
Non-current portion of operating lease liabilities	$ 6,044	$ 3,170	$ 3,553

XML 48 R38.htm IDEA: XBRL DOCUMENT

Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jul. 31, 2020 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	$ 1,117
2022	1,851
2023	1,818
2024	1,844
2025	1,867
Thereafter	7,268
Total	$ 15,765

XML 49 R39.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	3 Months Ended
Related Party Transactions (Details) - USD ($)	Jul. 31, 2020	Jul. 31, 2019
Related Party Transaction [Line Items]
Due to related parties	$ 7,400
Board Member One \| Board Member
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	18,000	$ 18,000
Board Member Two \| Board Member
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	$ 5,600	$ 15,200

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " "PA2Y1_WEJDI\! =& $P @ &M LV 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 +P O , , !]V@ ! end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 72 265 1 false 24 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://championsoncology.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://championsoncology.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Sheet http://championsoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS??? EQUITY Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Organization, Use of Estimates and Basis of Presentation Sheet http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation Organization, Use of Estimates and Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://championsoncology.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue Sheet http://championsoncology.com/role/AccountsReceivableUnbilledServicesAndDeferredRevenue Accounts Receivable, Unbilled Services and Deferred Revenue Notes 9 false false R10.htm 2104100 - Disclosure - Revenue from Contracts with Customers Sheet http://championsoncology.com/role/RevenueFromContractsWithCustomers Revenue from Contracts with Customers Notes 10 false false R11.htm 2105100 - Disclosure - Property and Equipment Sheet http://championsoncology.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 2106100 - Disclosure - Share-Based Payments Sheet http://championsoncology.com/role/ShareBasedPayments Share-Based Payments Notes 12 false false R13.htm 2108100 - Disclosure - Leases Sheet http://championsoncology.com/role/Leases Leases Notes 13 false false R14.htm 2109100 - Disclosure - Related Party Transactions Sheet http://championsoncology.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 2110100 - Disclosure - Commitments and Contingencies Sheet http://championsoncology.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2202202 - Disclosure - Significant Accounting Policies (Policies) Sheet http://championsoncology.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://championsoncology.com/role/SignificantAccountingPolicies 16 false false R17.htm 2302301 - Disclosure - Significant Accounting Policies (Tables) Sheet http://championsoncology.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://championsoncology.com/role/SignificantAccountingPolicies 17 false false R18.htm 2303301 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue (Tables) Sheet http://championsoncology.com/role/AccountsReceivableUnbilledServicesAndDeferredRevenueTables Accounts Receivable, Unbilled Services and Deferred Revenue (Tables) Tables http://championsoncology.com/role/AccountsReceivableUnbilledServicesAndDeferredRevenue 18 false false R19.htm 2304301 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://championsoncology.com/role/RevenueFromContractsWithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://championsoncology.com/role/RevenueFromContractsWithCustomers 19 false false R20.htm 2305301 - Disclosure - Property and Equipment (Tables) Sheet http://championsoncology.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://championsoncology.com/role/PropertyAndEquipment 20 false false R21.htm 2306301 - Disclosure - Share-Based Payments (Tables) Sheet http://championsoncology.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://championsoncology.com/role/ShareBasedPayments 21 false false R22.htm 2308301 - Disclosure - Leases (Tables) Sheet http://championsoncology.com/role/LeasesTables Leases (Tables) Tables http://championsoncology.com/role/Leases 22 false false R23.htm 2401401 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Details) Sheet http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentationDetails Organization, Use of Estimates and Basis of Presentation (Details) Details http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation 23 false false R24.htm 2402403 - Disclosure - Significant Accounting Policies - Narrative (Details) Sheet http://championsoncology.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies - Narrative (Details) Details 24 false false R25.htm 2402404 - Disclosure - Significant Accounting Policies - Calculation of Earnings Per Share (Details) Sheet http://championsoncology.com/role/SignificantAccountingPoliciesCalculationOfEarningsPerShareDetails Significant Accounting Policies - Calculation of Earnings Per Share (Details) Details 25 false false R26.htm 2402405 - Disclosure - Significant Accounting Policies - Summary of Potentially Antidilutive Securities (Details) Sheet http://championsoncology.com/role/SignificantAccountingPoliciesSummaryOfPotentiallyAntidilutiveSecuritiesDetails Significant Accounting Policies - Summary of Potentially Antidilutive Securities (Details) Details 26 false false R27.htm 2403402 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) Sheet http://championsoncology.com/role/AccountsReceivableUnbilledServicesAndDeferredRevenueSummaryOfAccountsReceivableAndUnbilledServicesDetails Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Accounts Receivable and Unbilled Services (Details) Details 27 false false R28.htm 2403403 - Disclosure - Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) Sheet http://championsoncology.com/role/AccountsReceivableUnbilledServicesAndDeferredRevenueSummaryOfDeferredRevenueDetails Accounts Receivable, Unbilled Services and Deferred Revenue - Summary of Deferred Revenue (Details) Details 28 false false R29.htm 2404402 - Disclosure - Revenue from Contracts with Customers (Details) Sheet http://championsoncology.com/role/RevenueFromContractsWithCustomersDetails Revenue from Contracts with Customers (Details) Details http://championsoncology.com/role/RevenueFromContractsWithCustomersTables 29 false false R30.htm 2405402 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://championsoncology.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 30 false false R31.htm 2405403 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://championsoncology.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Details 31 false false R32.htm 2406402 - Disclosure - Share-Based Payments - Narrative (Details) Sheet http://championsoncology.com/role/ShareBasedPaymentsNarrativeDetails Share-Based Payments - Narrative (Details) Details 32 false false R33.htm 2406403 - Disclosure - Share-Based Payments - Allocation of Share Based Compensation Expense (Details) Sheet http://championsoncology.com/role/ShareBasedPaymentsAllocationOfShareBasedCompensationExpenseDetails Share-Based Payments - Allocation of Share Based Compensation Expense (Details) Details 33 false false R34.htm 2406404 - Disclosure - Share-Based Payments - Valuation Assumptions for Stock Options (Details) Sheet http://championsoncology.com/role/ShareBasedPaymentsValuationAssumptionsForStockOptionsDetails Share-Based Payments - Valuation Assumptions for Stock Options (Details) Details 34 false false R35.htm 2406405 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details) Sheet http://championsoncology.com/role/ShareBasedPaymentsSummaryOfStockOptionActivityDetails Share-Based Payments - Summary of Stock Option Activity (Details) Details 35 false false R36.htm 2408402 - Disclosure - Leases (Details) Sheet http://championsoncology.com/role/LeasesDetails Leases (Details) Details http://championsoncology.com/role/LeasesTables 36 false false R37.htm 2408403 - Disclosure - Leases - ROU Assets and Lease Liabilities (Details) Sheet http://championsoncology.com/role/LeasesRouAssetsAndLeaseLiabilitiesDetails Leases - ROU Assets and Lease Liabilities (Details) Details 37 false false R38.htm 2408404 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://championsoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 38 false false R39.htm 2409401 - Disclosure - Related Party Transactions (Details) Sheet http://championsoncology.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://championsoncology.com/role/RelatedPartyTransactions 39 false false All Reports Book All Reports csbr-20200731.xml csbr-20200731.xsd csbr-20200731_cal.xml csbr-20200731_def.xml csbr-20200731_lab.xml csbr-20200731_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 55 0001628280-20-013559-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-20-013559-xbrl.zip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end